FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
FDA General

RFK Jr. Tones Down Vaccine Skepticism in Run Up to Midterms

HHS secretary Robert F. Kennedy Jr. curtails his public commentary on vaccines as part of a deliberate political strategy by the Trump administration ...

latest-news-card-1
Human Drugs

America First Fee Incentives Discussed in PDUFA Meeting

Minutes of the 3/10 and 3/12 PDUFA 8 reauthorization steering committee sessions, progress was reported on the America First fee incentive discussion,...

latest-news-card-1
Marketing

Alymsys Patient Brochure False or Misleading: FDA

The CDER Office of Prescription Drug Promotion says an Amneal patient brochure for its Avastin biosimilar Alymsys is false or misleading in several wa...

latest-news-card-1
Human Drugs

Vanda Blasts FDA Plan to Lengthen Drug Review Times

Vanda Pharmaceuticals says FDA should withdraw a legislative proposal in its budget package that the company says would lengthen NDA review times and ...

latest-news-card-1
FDA General

Inspection Cites Thermo Fisher Manufacturing Facility

FDA cites GMP deficiencies at a facility operated by Thermo Fisher Scientific (Patheon Italia unit) in Ferentino, Italy.

Medical Devices

FDA, Device Industry Reach Agreement on MDUFA VI

FDA and the device industry are nearing a final agreement on the next round of Medical Device User Fee Act (MDUFA VI) negotiations.

latest-news-card-1
Medical Devices

Medline Class 1 Recall of Angiographic Control Syringes

Medline Industries recalls (Class 1) its angiographic control syringes, warning the devices could cause severe injury or death.

Human Drugs

Granules Steps Up Oversight at Troubled India Facility

Granules India Ltd tightens oversight of its manufacturing operations at its largest facility based on FDA-documented compliance issues outlined in a ...

latest-news-card-1
Marketing

Will the Push for DTC Pre-Review Grow?

Two Hyman, Phelps & McNamara attorneys describe the impacts on industry if FDA responds to a congressional push for more pre-review of direct-to-consu...

Marketing

Lucemyra Web Site Home Page False or Misleading: FDA

FDA cautions BioCorRx about false and misleading information on the Web site home page for its Lucemyra.